drugset / Trial / NCT01163929
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess whether a combination of chemotherapy, Trastuzumab and RAD001 will result in no evidence of microscopic disease at the time of surgery in 50% of enrolled patients.
Timeline
- Start
- 2010-07
- Primary completion
- 2012-03
- Completion
- 2012-03
Outcome
Outcome not reported
Stopped (Enrollment): “Study closed by Protocol Review Monitoring Committee because of lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |